TrialJournal of the peripheral nervous system : JPNS2025

Results From a Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ANX005, a C1q Inhibitor, in Patients With Guillain-Barré Syndrome.

Quazi Deen Mohammad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.